Page 51 - ஜப்பானிய அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Le Japon va arrêter les entrées d étrangers non résidents sur son territoire
tvanouvelles.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tvanouvelles.ca Daily Mail and Mail on Sunday newspapers.
Обзор московских событий в СМИ за 25 декабря
mskagency.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mskagency.ru Daily Mail and Mail on Sunday newspapers.
Минздрав Японии определил приоритеты при вакцинации против COVID-19
regnum.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from regnum.ru Daily Mail and Mail on Sunday newspapers.
Published: Dec 23, 2020
SAN MATEO, Calif., Dec. 23, 2020 /PRNewswire/
Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (ClinicalTrials.gov Identifier: NCT04305795) has enrolled and treated its first patient in the United States, at The University of Texas MD Anderson Cancer Center, Houston, Texas. Approximately 74 patients are planned for this trial in Head and Neck Squamous Cell Carcinoma (HNSCC) and Cutaneous Squamous Cell Carcinoma (CuSCC).
The trial will enroll three cohorts of patients within distinct populations – all with locally advanced, recurrent and/or metastatic HNSCC or locally advanced or metastatic CuSCC. Primary endpoints of this study include safety, tolerability, and tumor response of the ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy.
Image source: Getty Images.
1. BioCryst Pharmaceuticals
BioCryst is on the cusp of a major transformation and may soon cross the $2 billion market capitalization threshold to become a mid-cap stock. On Dec. 3, the U.S. Food and Drug Administration (FDA) approved the company s lead asset, Orladeyo (berotralstat), as the first oral, once-daily pill to prevent hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years or older. HAE is a rare genetic condition causing painful attacks of swelling in the face, feet, hands, and genitals, and affects one in 67,000 individuals.
The market considers this to be a major win, since BioCryst s market capitalization has swooped up from $900 million just prior to the FDA s announcement to around $1.4 billion as of Dec. 17. Share prices are up over 138% so far in this year.